Real-World Analyses of the Treatment Conditions in Patients Initiating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor in Taiwan
Source : https://www.jstage.jst.go.jp/article/jat/advpub/0/advpub_63789/_article
Aims: Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor is a powerful low density lipoprotein cholesterol (LDL-C)-lowering therapy, but this drug is expensive. This study aimed to describe the real-world treatment...
Conclusions: In the real-world practice in Taiwan, the LDL-C reduction efficacy of PCSK9 inhibitors was slightly lower than that reported in the clinical trials. The use of non-standard-dosing PCSK9 inhibitors was not uncommon in Taiwan.
Share
Recent Advances in Gene Therapy for Familial Hypercholesterolemia: An Update Review - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36431249/
(1) Background: Existing lipid-lowering therapies have difficulty in achieving lipid target levels in patients with familial hypercholesterolemia (FH), especially in the treatment of patients with homozygous familial hypercholesterolemia. (2) Method:...
Conclusion: Gene therapy is being widely used for the lipid-lowering treatment of FH patients and has shown excellent therapeutic promise, but the current delivery efficiency, economic burden, immunogenicity and the precision of gene therapy can be further optimized.
Share
Cardiovascular Risk Profile and Lipid Management in the Population-Based Cohort Study LATINO: 20 Years of Real-World Data - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36431309/
The rising prevalence of cardiovascular (CV) risk factors in Portugal has translated into more than 35,000 annual deaths due to CV diseases. We performed a multicenter observational cohort study encompassing...
Conclusions/Relevance: There are clear opportunities to optimize LDL-C management in routine clinical practice. The prescription of LLT according to CV risk represents an important missed treatment opportunity.
Share
Effect of evolocumab on fasting and post fat load lipids and lipoproteins in familial dysbetalipoproteinemia
Source : https://www.lipidjournal.com/article/S1933-2874(22)00291-4/fulltext
Familial dysbetalipoproteinemia (FD), also known as 'remnant removal disease', is the second most common monogenic lipid disorder after heterozygous familial hypercholesterolemia (heFH), with an estimated prevalence of 1 in 850...
Conclusions: Evolocumab added to standard lipid-lowering therapy significantly reduced fasting and absolute post fat load concentrations of non-HDL-C, apoB and other atherogenic lipids and lipoproteins in FD patients. The clinically significant decrease in lipids and lipoproteins can be expected to translate into a reduction in CVD risk in...
Share
-
Lipid Management Connect3yrKey Takeaways • Source: Journal of Clinical Lipidology • Conclusion: “Evolocumab added to standard lipid-lowering therapy significantly reduced fasting and absolute post fat load concentrations of non-HDL-C, apoB and other atherogenic lipids and lipoproteins Show More
World Heart Federation Cholesterol Roadmap 2022
Source : https://globalheartjournal.com/article/10.5334/gh.1154/
Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of death globally despite major advances in our understanding of the pathophysiology of atherosclerosis, its consequences and the development of new preventive...
Conclusions: The adverse effects of LDL-cholesterol and apo B containing lipoprotein exposure are cumulative and result in ASCVD. These are preventable by implementation of different strategies, aimed at efficiently tackling atherosclerosis at different stages throughout the human life-course. Preventive strategies should therefore be updated...
Share